IL4 IL13 and IL13 targeted biologic therapies in mild to moderate AD

CE / CME

Mapping IL-13 to the Clinical Manifestations of Atopic Dermatitis

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Released: May 07, 2025

Expiration: May 06, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Amy, a 36-year-old woman with severe atopic dermatitis (AD), presents with persistent symptoms including redness, itching, and scaling despite using topical corticosteroids and emollients. Her condition has worsened during the past year, and she reports sleep disruption caused by itching. Laboratory findings show an elevated immunoglobulin E level and eosinophilia. Based on the role of interleukin (IL)-13 in AD, which of the following best describes its pathophysiologic contributions to Amy’s clinical manifestations?